Anebulo Pharmaceuticals Inc (ANEB)
3.04
0.00 (0.00%)
USD |
NASDAQ |
May 08, 16:00
Anebulo Pharmaceuticals Enterprise Value: 72.19M for May 8, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 08, 2024 | 72.19M |
| May 07, 2024 | 72.19M |
| May 06, 2024 | 69.86M |
| May 03, 2024 | 69.86M |
| May 02, 2024 | 74.27M |
| May 01, 2024 | 70.12M |
| April 30, 2024 | 68.56M |
| April 29, 2024 | 64.67M |
| April 26, 2024 | 63.47M |
| April 25, 2024 | 65.82M |
| April 24, 2024 | 65.71M |
| April 23, 2024 | 63.63M |
| April 22, 2024 | 62.86M |
| April 19, 2024 | 65.45M |
| April 18, 2024 | 67.27M |
| April 17, 2024 | 71.15M |
| April 16, 2024 | 70.12M |
| April 15, 2024 | 70.09M |
| April 12, 2024 | 68.69M |
| April 11, 2024 | 68.30M |
| April 10, 2024 | 60.78M |
| April 09, 2024 | 66.74M |
| April 08, 2024 | 65.45M |
| April 05, 2024 | 65.46M |
| April 04, 2024 | 67.91M |
| Date | Value |
|---|---|
| April 03, 2024 | 67.91M |
| April 02, 2024 | 66.75M |
| April 01, 2024 | 68.30M |
| March 28, 2024 | 67.78M |
| March 27, 2024 | 65.45M |
| March 26, 2024 | 60.78M |
| March 25, 2024 | 58.12M |
| March 22, 2024 | 58.19M |
| March 21, 2024 | 55.60M |
| March 20, 2024 | 55.60M |
| March 19, 2024 | 55.60M |
| March 18, 2024 | 55.60M |
| March 15, 2024 | 59.23M |
| March 14, 2024 | 56.11M |
| March 13, 2024 | 56.11M |
| March 12, 2024 | 56.89M |
| March 11, 2024 | 65.19M |
| March 08, 2024 | 69.86M |
| March 07, 2024 | 68.71M |
| March 06, 2024 | 64.41M |
| March 05, 2024 | 64.15M |
| March 04, 2024 | 67.78M |
| March 01, 2024 | 64.67M |
| February 29, 2024 | 63.89M |
| February 28, 2024 | 65.45M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
26.67M
Minimum
Oct 21 2022
204.93M
Maximum
May 21 2021
85.54M
Average
63.55M
Median
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.636M |
| Palatin Technologies Inc | 23.59M |
| iBio Inc | 16.49M |
| Theriva Biologics Inc | -13.03M |
| Oragenics Inc | 3.844M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.717M |
| Total Expenses (Quarterly) | 2.760M |
| EPS Diluted (Quarterly) | -0.11 |
| Earnings Yield | -13.82% |